HQ Team
October 2, 2024: Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating new products planned by the decade’s end.
“The new facility will expand production of the company’s portfolio and pipeline of innovative biologics in support of Johnson & Johnson’s broader plan to advance more than 70 novel therapy and product expansion filings and launches,” according to a company statement.
Construction is anticipated to begin in the first half of 2025.
The new facility will expand the production of Johnson & Johnson’s innovative biologic medicines in oncology, immunology, and neuroscience, with technology focused on enabling efficient manufacturing operations.
‘Resilient supply chain’
The site will employ about 420 full-time, highly skilled employees.
“A strong, global supply chain is crucial, and we purposefully invest to ensure our transformational medicines reliably and efficiently reach patients,” said Dapo Ajayi, Vice President, Innovative Medicine Supply Chain, at Johnson & Johnson.
“We are investing in capacity and new technologies to enhance our industry-leading capabilities and ensure a resilient supply chain for the future.
“North Carolina is an important hub for biopharmaceutical manufacturing and talent,” she said.
New products introduced within the past five years accounted for approximately 25% of sales in 2023. The company invested $15.1 billion in research and development in the same year.
In 2023, worldwide sales increased 6.5% to $85.2 billion as compared to an increase of 1.6% in 2022, according to the annual report.
Innovative medicine segment sales, driven by immunology and oncology products, in 2023 were $54.8 billion, an increase of 4.2% from 2022.
